Seite 3 von 5
Neuester Beitrag: 27.08.22 15:11
|Eröffnet am:||05.12.12 07:53||von: buran||Anzahl Beiträge:||106|
|Neuester Beitrag:||27.08.22 15:11||von: Vassago||Leser gesamt:||23.467|
|Seite: < 1 | 2 | | 4 | 5 >|
buran: La Jolla Pharmaceutical Company Analyst
NEW YORK, July 17, 2014
NEW YORK, July 17, 2014 /PRNewswire/ -- La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
In January 2014, the Decision Resources Group (DRG) -- a subsidiary of Piramal Enterprises offering information and insights on important sectors of the healthcare industry -- estimated that the total chronic kidney disease (CKD) market was worth around $11 billion in 2012. However, DRG only sees that market growing another $700 million by 2022 due to generic and biosimilar competition in the G7 markets and changes in reimbursement practices in the US. Nevertheless, LJPC believes it can capture a significant portion of the market with their GCS-100 drug candidate given that nearly 49 million adults in the United States suffered from CKD resulting in close to 89,000 deaths in 2010, while close to 550,000 were treated for end-stage renal disease (ESRD).
A full in-depth analyst report on LJPC that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at firstname.lastname@example.org. For any urgent concerns or inquiries please contact us at email@example.com.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.
Quelle: PR Newswire
buran: LJPC 21-10
21.10.14 9,49 9,96§9,20 9,84 $ 119.106 1,11 M
buran: #54 klingt wie schmuddelich buran
buran: jo odda wie Lidda Dar uffe Bäm Dschorannimo #55
buran: Turbine Frankfurt Echtzeit::::
steven-bln: Soso, La Jolla wieder am Auferstehen. Haben sie
steven-bln: Wer La Jolla von früher kennt, weiss was die Firma
buran: drüben über 278 Tausend RT getickert
buran: gleich 40.000 Glitzerlinge
buran: Dynamo Frankfurt:::
buran: La Jolla Pharmaceutical Company Announces Positive
— Primary efficacy endpoint analysis highly statistically significant (p<0.00001)
— Trend toward longer survival observed
— New Drug Application planned for second half of 2017
— Company to host conference call and webcast at 8:30 a.m. EST on Monday, Feb. 27, 2017
SAN DIEGO–(BUSINESS WIRE)–Feb. 27, 2017– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), today announced positive top-line results from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) in patients with catecholamine resistant hypotension (CRH). http://lajollapharmaceutical.com/2017/02/...hase-3-study-of-ljpc-501/
buran: letzte aktuelle ask Nasdaq
Balu4u: Buy Rating
Vassago: LJPC 6,01$ (-43%)
Vassago: LJPC 6,76$ (+7%)